MT-2 (Melanotan II) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has been investigated extensively in preclinical research for its interactions with the melanocortin receptor system. As one of the most studied melanocortin peptides, MT-2 has attracted scientific interest across multiple domains — from pigmentation biology and UV-independent melanogenesis to central nervous system signaling, appetite regulation, and energy homeostasis. Its high-affinity binding to MC1R, MC3R, MC4R, and MC5R makes it a versatile research tool for exploring the breadth of melanocortin signaling in laboratory settings.
This guide provides an overview of MT-2‘s known mechanisms, receptor pharmacology, and the key research areas where it has been examined in preclinical models. All references to studies and findings reflect laboratory and animal-based research and are intended to support scientific understanding only.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. MT-2 is not approved for human use and is intended strictly for licensed research applications.
MT-2 - 10MG — Research-Grade Reference Material MT-2 - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
MOTS-C - 10MG
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
5-Amino-1MQ - 50mg
$115.00$86.25 with 1st order
Frequently Asked Questions
What is MT-2 (Melanotan II)?
MT-2, or Melanotan II, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed at the University of Arizona as a research compound and has been studied for its ability to activate multiple melanocortin receptors in preclinical models.
Which melanocortin receptors does MT-2 bind to?
Research indicates that MT-2 demonstrates high binding affinity for MC1R, MC3R, MC4R, and MC5R. This broad receptor profile distinguishes it from more selective analogues and makes it a useful tool in studies exploring melanocortin system signaling across multiple tissues.
What has MT-2 been studied for in preclinical research?
Preclinical studies have investigated MT-2 in the context of melanogenesis and pigmentation, energy regulation and appetite suppression, sexual arousal pathways via MC4R, anti-inflammatory signaling, and body composition research in rodent models.
How does MT-2 differ from PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is a metabolite of MT-2 that was developed as a more selective melanocortin compound. While MT-2 binds broadly across multiple MC receptors, PT-141 primarily targets MC3R and MC4R. PT-141 research has focused more narrowly on CNS-mediated arousal pathways in comparison to MT-2’s wider receptor profile.
Is MT-2 the same as a tanning injection?
MT-2 has been colloquially associated with “tanning peptides” due to its observed stimulation of melanogenesis in animal models. However, it is a research compound and is not approved as a cosmetic or medical product. Any discussion of its effects on pigmentation refers strictly to preclinical findings.
What is the relationship between MC4R and the research interest in MT-2?
MC4R is a centrally expressed receptor involved in energy balance, food intake regulation, and sexual function signaling pathways. MT-2’s affinity for MC4R has driven significant research interest into its potential as a probe compound for studying these pathways in animal models of obesity and metabolic dysfunction.
Where can researchers source MT-2 for laboratory use?
MT-2 is available for licensed laboratory research from specialized peptide suppliers. Researchers should verify purity documentation (HPLC and mass spectrometry certificates) before use. SourcePeptides.co offers MT-2 in 10MG research quantities.
Background: Origins and Development of MT-2
MT-2 was developed in the 1980s and 1990s by researchers at the University of Arizona, led by Dr. Victor Hruby and colleagues, as part of a broader program to identify synthetic melanocortin agonists with improved stability and receptor potency compared to the endogenous α-MSH peptide. The natural hormone α-MSH is a 13-amino acid peptide derived from proopiomelanocortin (POMC) cleavage and is known to regulate a wide range of physiological processes through the five-receptor melanocortin system (MC1R–MC5R).
MT-2 - 10MG — Research-Grade Reference Material MT-2 - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
MOTS-C - 10MG
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
5-Amino-1MQ - 50mg
$115.00$86.25 with 1st order
MT-2 is a cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) that incorporates key structural modifications — including a D-phenylalanine substitution and cyclic lactam bridge — that confer greater metabolic stability and receptor binding potency than the linear native ligand. These properties have made MT-2 a widely used pharmacological probe in melanocortin receptor biology research.
MT-2 – 10MG for laboratory research →
Melanocortin Receptor Pharmacology: How MT-2 Is Studied
The melanocortin system comprises five G-protein-coupled receptors (GPCRs), each distributed in distinct tissues and associated with different physiological regulatory roles. MT-2’s broad agonist profile across four of these five receptors makes it one of the most extensively mapped melanocortin ligands in basic science research.
MC1R: Pigmentation and Melanogenesis Research
MC1R is predominantly expressed on melanocytes and is the primary receptor mediating eumelanin (dark pigment) synthesis. Studies have investigated MT-2’s ability to activate MC1R-driven cAMP signaling cascades, which in turn upregulate tyrosinase activity and promote melanin production in cell and animal models. Research in rodent models showed that systemic administration of MT-2 resulted in dose-dependent increases in skin and coat pigmentation — findings that underpinned early interest in the compound as a tanning peptide model. Research into MC1R also intersects with broader peptide classification frameworks due to its highly specific receptor-targeted action.
MC3R and MC4R: Energy Balance and Appetite Studies
MC3R and MC4R are centrally expressed receptors implicated in hypothalamic regulation of food intake and energy expenditure. MT-2 has been studied extensively in rodent models of obesity, where researchers have observed reductions in food intake and body weight following MC3R/MC4R activation. These findings have contributed to the understanding of the central melanocortin circuit as a target in metabolic research. This overlaps conceptually with research on other metabolic peptides — for instance, MOTS-C research on mitochondrial metabolism highlights complementary pathways through which energy homeostasis is studied in peptide science.
MC4R and Sexual Arousal Signaling
One of the most discussed research areas for MT-2 involves MC4R-mediated pathways in the CNS associated with sexual arousal and erectile function. Preclinical studies in rodent models reported pro-erectile effects attributed to hypothalamic MC4R activation, which prompted the development of PT-141 (bremelanotide) as a more targeted derivative. These observations established MT-2 as an important early research tool in melanocortin-CNS interaction studies. The PT-141 research overview provides additional context on how this mechanistic branch evolved from MT-2 research.
MC5R: Exocrine Gland and Immune Research
MC5R is expressed in peripheral tissues, including exocrine glands and immune cells. Research into MT-2’s interaction with MC5R has explored its potential role in regulating sebaceous gland activity and inflammatory mediator production. Some animal studies have examined anti-inflammatory effects of melanocortin agonism that may be partially mediated through this receptor subtype.
Tanning and Melanogenesis: Preclinical Research Summary
Among MT-2’s most studied properties in animal models is its capacity to stimulate melanogenesis independent of UV radiation. Traditional UV-induced tanning occurs when UV light damages DNA, triggering POMC peptide release and subsequent α-MSH/MC1R activation. MT-2 bypasses this pathway entirely by directly engaging MC1R, effectively mimicking the downstream signaling that results in eumelanin synthesis.
Rodent studies from the 1990s and early 2000s demonstrated that MT-2 administration produced visible pigmentation changes consistent with eumelanin upregulation. Researchers also noted that the effect appeared dose-dependent and was reversible upon cessation in many animal models. These mechanistic findings have made MT-2 a useful compound for studying the MC1R–cAMP–tyrosinase axis in dermatological biology research.
Importantly, a parallel line of research has investigated whether MC1R-driven melanogenesis might interact with UV-protective pathways, as eumelanin provides greater photoprotection than pheomelanin (the lighter pigment associated with fair skin and MC1R loss-of-function variants). These mechanistic questions remain active areas of basic science investigation.
MT-2 – 10MG research quantity available →
MT-2 and Body Composition Research
The MC3R/MC4R agonist activity of MT-2 has generated significant interest in metabolic and body composition research. Several key findings have emerged from preclinical literature:
- Anorexigenic effects: Animal studies have consistently shown that MT-2 administration reduces spontaneous food intake, attributed to hypothalamic MC4R activation that suppresses orexigenic (appetite-stimulating) neuropeptide signaling.
- Energy expenditure modulation: Some rodent studies have reported increases in resting energy expenditure following melanocortin agonism, suggesting a dual mechanism of reduced intake and increased output.
- Fat mass reduction: In diet-induced obesity models, MT-2 has been observed to reduce adiposity, though the relative contributions of appetite suppression versus direct metabolic effects remain a subject of ongoing investigation.
- Interaction with leptin pathways: Research has explored the overlap between melanocortin signaling and leptin receptor pathways in the hypothalamus, with MT-2 used as a probe to dissect these interconnected circuits.
These findings place MT-2 research in an interesting comparative position alongside newer metabolic peptides. The GLP-1 research literature on satiety signaling provides a useful contrast — while GLP-1 acts peripherally on vagal afferents and hypothalamic nuclei via incretin pathways, MT-2 acts more directly through central melanocortin circuitry.
Anti-Inflammatory and Neuroprotective Research Angles
Beyond pigmentation and metabolic research, MT-2 has been studied in the context of inflammation and CNS signaling. The melanocortin system has established anti-inflammatory properties, and several preclinical models have examined whether MT-2’s broad receptor agonism produces measurable effects on inflammatory cytokine profiles.
- Some animal studies have reported reductions in pro-inflammatory cytokines (including TNF-α and IL-6) following melanocortin agonist administration in experimental inflammation models.
- Neuroprotective effects have been proposed based on MC4R distribution in the CNS and its role in modulating neuroinflammatory cascades.
- Preclinical ischemia models have examined melanocortin receptor activation as a potential protective mechanism, though these findings are early-stage and exploratory.
Researchers interested in CNS-targeted peptide research may find useful context in comparing MT-2’s CNS receptor activity with other neuroactive peptides. For example, Semax’s BDNF-mediated neuroprotective research represents an alternative mechanistic pathway through which neuroprotection has been studied in peptide science.
MT-2 vs PT-141: Key Research Distinctions
| Feature | MT-2 (Melanotan II) | PT-141 (Bremelanotide) |
|---|---|---|
| Receptor profile | MC1R, MC3R, MC4R, MC5R | MC3R, MC4R (primary) |
| Pigmentation research | Strong MC1R-driven melanogenesis data | Minimal pigmentation activity |
| Sexual arousal research | Preclinical MC4R data; foundational compound | Direct derivative; more selective CNS focus |
| Metabolic research | Appetite suppression; body composition models | Less studied in metabolic contexts |
| Research breadth | Multi-receptor; broad experimental utility | Narrower; more targeted CNS applications |
| Development stage | Preclinical research compound | FDA-approved (Vyleesi) for HSDD in women |
Choose MT-2 if…
- Your research focus involves MC1R-driven melanogenesis or pigmentation biology
- You are studying multi-receptor melanocortin pharmacology across MC1R, MC3R, MC4R, and MC5R simultaneously
- Your laboratory is investigating metabolic or appetite regulation models using central melanocortin circuit probes
- You require a foundational melanocortin agonist with a well-established preclinical literature baseline
Choose PT-141 if…
- Your research focuses specifically on MC3R/MC4R-mediated CNS arousal signaling pathways
- You want a more selective melanocortin probe with reduced MC1R and MC5R activity
- You are examining neural circuits associated with sexual arousal independent of pigmentation effects
PT-141 – 10MG Nasal Spray for research →
Laboratory Handling and Research Considerations
For researchers working with MT-2 in preclinical settings, several practical considerations are relevant:
- Stability: As a cyclic peptide, MT-2 demonstrates improved stability compared to linear analogues, though proper storage at −20°C under desiccated conditions is recommended to preserve integrity.
- Reconstitution: MT-2 is typically reconstituted in bacteriostatic water for laboratory applications. Researchers should verify peptide purity via HPLC and mass spectrometry documentation prior to experimental use.
- Dose selection: Published rodent studies have employed a range of administration protocols. Researchers should consult primary literature for dose-response data appropriate to their specific experimental model.
- Receptor selectivity considerations: Given MT-2’s broad receptor profile, researchers should design control experiments carefully to attribute observed effects to specific receptor subtypes, particularly when distinguishing MC1R-mediated pigmentation effects from MC4R-mediated metabolic or behavioral effects.
Researchers exploring the intersection of melanocortin and broader hormonal signaling may also find it useful to reference kisspeptin peptide research, as both systems intersect with hypothalamic control of reproductive and metabolic physiology.
Where These Fit in Your Research Library
MT-2 is a foundational melanocortin research compound that complements a range of peptide research programs. Researchers building a multi-target library may also consider:
MT-2 – 10MG (primary melanocortin agonist for research) →
PT-141 – 10MG Nasal Spray (selective MC3R/MC4R research) →
Semax – 10MG Nasal Spray (CNS neuroprotective signaling research) →
For the full research peptide catalog, visit the SourcePeptides.co product library.
Final Takeaway
MT-2 (Melanotan II) remains one of the most pharmacologically interesting synthetic melanocortin peptides in preclinical research. Its high-affinity binding across MC1R, MC3R, MC4R, and MC5R has enabled researchers to investigate a remarkably wide range of biological systems — from UV-independent melanogenesis and skin pigmentation biology to hypothalamic energy balance, central arousal signaling, and anti-inflammatory pathways. Its role as the precursor compound to PT-141 further cements its historical and mechanistic importance in melanocortin science.
For laboratory researchers seeking a well-characterized, multi-receptor melanocortin probe with a deep preclinical literature base, MT-2 represents an essential addition to any research program exploring the melanocortin system. As always, all research use should comply with applicable institutional and regulatory frameworks, and the compound should be handled strictly within a licensed laboratory research context.
Sources & Further Reading
- Hadley ME et al. — “Discovery and development of novel melanocortin agonists” — Pigment Cell Research (1996)
- Wikberg JE — “Melanocortin receptors: perspectives for novel drugs” — European Journal of Pharmacology (1999)
- Dorr RT et al. — “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study” — Life Sciences (1996)
- PubMed Search — Melanotan II melanocortin receptor research literature
- Cone RD — “Anatomy and regulation of the central melanocortin system” — Nature Neuroscience (2005)
